PUBLISHER: Grand View Research | PRODUCT CODE: 1363182
PUBLISHER: Grand View Research | PRODUCT CODE: 1363182
The global pharmaceutical collaborative robots market size is expected to reach USD 140.58 million by 2030, registering a CAGR of 9.7% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is witnessing a surge in demand as the industry embraces automation to enhance efficiency and compliance. Rapid technological advancements have led to the development of more versatile and user-friendly collaborative robots (cobots) that seamlessly integrate into pharmaceutical workflows. These robots are addressing challenges, such as labor shortages, intricate regulatory requirements, and the need for flexible manufacturing. As pharmaceutical companies strive for agility & innovation, adopting collaborative robots is set to continue, reshaping the industry by improving productivity, quality, and worker safety.
The COVID-19 pandemic has propelled the adoption of pharmaceutical collaborative robots, or cobots, as the industry sought to ensure production continuity while prioritizing worker safety. The pandemic-induced labor shortages and the need for social distancing accelerated the integration of cobots into pharmaceutical operations, enabling tasks to be performed efficiently without compromising human health. As a result, cobots have played a pivotal role in maintaining pharmaceutical supply chains, and supporting R&D efforts. In the rapidly evolving landscape of pharmaceutical manufacturing, the integration of collaborative robots, or cobots, has emerged as a pivotal strategy for enhancing operational efficiency, ensuring regulatory compliance, and driving innovation.
As the demand for pharmaceutical products continues to grow, key players in the industry are strategically leveraging cobot technology to stay competitive and meet the market's evolving needs. These industry leaders are implementing innovative approaches to harness the capabilities of cobots, ranging from streamlined production processes to R&D acceleration. For instance, in February 2021, ABB is enhancing its collection of cobots by introducing the GoFa and SWIFTI cobot families, which provide increased payloads and velocities. These additions complement ABB's cobot offerings, namely YuMi and Single Arm YuMi. The amplified capabilities of these new cobots are poised to propel ABB's presence in growing sectors like electronics, healthcare, consumer goods, logistics, and food & beverage.